Stoke Therapeutics, Inc. Operating Lease Right-of-Use Assets
Stoke Therapeutics, Inc. (STOK) had Operating Lease Right-of-Use Assets of $1.87 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-03
- 2026-06-30: Operating Lease, Right-of-Use Asset $1.87M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $2.49M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $3.10M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $3.71M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $1.87M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $2.49M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $3.10M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $3.71M 10-Q · filed 2025-11-04 |
| 2025-07-31 | $1.80M 10-Q · filed 2026-08-03 |
| 2025-06-30 | $3.22M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $3.83M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $4.34M 10-K · filed 2026-03-16 |
| 2024-09-30 | $4.93M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $5.50M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $6.06M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $6.61M 10-K · filed 2025-03-18 |
| 2023-09-30 | $3.08M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $3.65M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $4.20M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $4.75M 10-K · filed 2024-03-25 |
| 2022-09-30 | $5.29M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $5.83M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $4.56M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $4.94M 10-K · filed 2023-03-06 |
| 2021-09-30 | $5.33M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $1.26M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $844.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | $1.11M 10-K · filed 2022-03-10 |
| 2020-09-30 | $1.38M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $1.64M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $1.90M 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |